Skip to main content

Advertisement

SpringerLink
Log in

High expression of constitutive photomorphogenic 1 (COP1) is associated with poor prognosis in bladder cancer

  • Original Article
  • Published:
Tumor Biology

Abstract

The present study was to investigate the expression and prognostic value of constitutive photomorphogenic 1 (COP1) in bladder cancer. In our study, real-time quantitative PCR (RT-PCR) was performed to detect 10 pairs of fresh bladder cancer (BCa) and adjacent noncancerous tissues. In addition, immunohistochemistry was utilized to detect the expression of COP1 in 174 clinical bladder cancer samples. What is more, the correlation of COP1 expression and clinicopathological features and clinical outcomes were analyzed. The expression levels of COP1 in clinical bladder cancer were much higher than that in paired adjacent noncancerous tissues (p < 0.0001). High expression of COP1 was closely related with differentiation (p = 0.040) and recurrence (p = 0.001) of patients with bladder cancer. Kaplan-Meier analysis revealed that the expression of COP1 was closely correlated with overall survival (p = 0.048) of bladder cancer, while, recurrence-free survival (p = 0.201). Moreover, Cox multivariate regression analyses showed that COP1 expression was an independent predictor of overall survival (OS; p = 0.027, hazard ratio = 2.127, confidence interval 0.814 to 9.736). Based on our data, the present study suggests that high expression of COP1 may be a novel biological indicator for evaluation of poor prognosis in bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011;59(6):1009–18.

    Article  CAS  PubMed  Google Scholar 

  2. Zhu Z, Wang X, Shen Z, Lu Y, Zhong S, Xu C. Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies. BMC Cancer. 2013;13:310.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer Journal international du cancer. 2015;136(5):E359–386.

    Article  CAS  PubMed  Google Scholar 

  4. van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430–42.

    Article  PubMed  Google Scholar 

  5. Ather MH, Nazim SM. New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer. Korean J Urology. 2015;56(8):553–64.

    Article  Google Scholar 

  6. Oderda M, Ricceri F, Pisano F, et al. Prognostic factors including Ki-67 and p53 in Bacillus Calmette-Guerin-treated non-muscle-invasive bladder cancer: a prospective study. Urol Int. 2013;90(2):184–90.

    Article  CAS  PubMed  Google Scholar 

  7. Lokeshwar VB, Schroeder GL, Selzer MG, et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer. 2002;95(1):61–72.

    Article  PubMed  Google Scholar 

  8. Jones A, Crew J. Vascular endothelial growth factor and its correlation with superficial bladder cancer recurrence rates and stage progression. Urol Clin North Am. 2000;27(1):191–7.

    Article  CAS  PubMed  Google Scholar 

  9. Soloway MS, Briggman V, Carpinito GA, et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 1996;156(2 Pt 1):363–7.

    Article  CAS  PubMed  Google Scholar 

  10. Deng XW, Caspar T, Quail PH. cop1: a regulatory locus involved in light-controlled development and gene expression in Arabidopsis. Genes Dev. 1991;5(7):1172–82.

    Article  CAS  PubMed  Google Scholar 

  11. Dornan D, Wertz I, Shimizu H, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature. 2004;429(6987):86–92.

    Article  CAS  PubMed  Google Scholar 

  12. Li YF, Wang DD, Zhao BW, et al. High level of COP1 expression is associated with poor prognosis in primary gastric cancer. Int J Biol Sci. 2012;8(8):1168–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Dornan D, Bheddah S, Newton K, et al. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 2004;64(20):7226–30.

    Article  CAS  PubMed  Google Scholar 

  14. Azemar MD, Comperat E, Richard F, Cussenot O, Roupret M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol Oncol. 2011;29(2):130–6.

    Article  PubMed  Google Scholar 

  15. Corcoran CA, Huang Y, Sheikh MS. The p53 paddy wagon: COP1, Pirh2 and MDM2 are found resisting apoptosis and growth arrest. Cancer Biol Ther. 2004;3(8):721–5.

    Article  CAS  PubMed  Google Scholar 

  16. Mariani O, Brennetot C, Coindre JM, et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell. 2007;11(4):361–74.

    Article  CAS  PubMed  Google Scholar 

  17. Wei W, Kaelin Jr WG. Good COP1 or bad COP1? In vivo veritas. J Clin Invest. 2011;121(4):1263–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Marine JC. Spotlight on the role of COP1 in tumorigenesis. Nat Rev Cancer. 2012;12(7):455–64.

    Article  CAS  PubMed  Google Scholar 

  19. Vitari AC, Leong KG, Newton K, et al. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature. 2011;474(7351):403–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Department of Urology, the Second Affiliated Hospital of Nanchang University, 330006, Nanchang, Jiangxi Province, People’s Republic of China

      Jianlong Li, Longwang Wang, Ruihai Xiao, Qiufeng Pan, Hongwei Huang & Renrui Kuang

    Authors
    1. Jianlong Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Longwang Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Ruihai Xiao
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Qiufeng Pan
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Hongwei Huang
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Renrui Kuang
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Renrui Kuang.

    Ethics declarations

    Conflicts of interest

    The authors declare that they have no competing interests.

    Additional information

    Jianlong Li and Longwang Wang contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Li, J., Wang, L., Xiao, R. et al. High expression of constitutive photomorphogenic 1 (COP1) is associated with poor prognosis in bladder cancer. Tumor Biol. 37, 8917–8922 (2016). https://doi.org/10.1007/s13277-015-4765-4

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s13277-015-4765-4

    Keywords

    Search

    Navigation